NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT04314219 2025-03-13
PTCy-PMAT
King Faisal Specialist Hospital & Research Center
Phase 3 Recruiting
NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
NCT01686334 2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2 Active not recruiting
NCT02789254 2023-12-28
FLYSYN-101
Synimmune GmbH
Phase 1/2 Completed
NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn
NCT01656252 2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2 Terminated
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT00725283 2018-08-07
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
GlaxoSmithKline
Phase 1 Completed
NCT01520558 2017-06-29
CNDO-109-AANK for AML in First Complete Remission (CR1)
Coronado Biosciences, Inc.
Phase 1/2 Unknown
NCT01471067 2017-04-28
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01843179 2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2 Withdrawn